Navigation Links
Telik Announces New TRAP Drug Discovery Agreement
Date:11/12/2008

PALO ALTO, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today an agreement to provide its TRAP(R) drug discovery technology to investigators at the Hospital for Special Surgery (HSS). The Research Division of HSS studies the mechanisms underlying musculoskeletal and autoimmune diseases to discover effective treatments for these disorders. HSS investigators will use Telik's TRAP technology to discover novel compounds that inhibit a key enzyme in cell signaling and migration.

"By efficiently identifying novel small molecules that affect biological targets, Telik's TRAP technology offers a unique opportunity to accelerate our research," said Carl Blobel, M.D., Ph.D., Professor of Medicine, Physiology, and Biophysics, and Director of the Arthritis and Tissue Degeneration Program at HSS. "We are interested in membrane bound enzymes and the biological effects that result from their modulation. Rapidly finding small molecules that inhibit these enzymes could lead to new ways to treat diseases for which there is significant unmet medical need."

"This partnership allows the world-class investigators at HSS to leverage our recent advances in TRAP technology to accelerate the discovery of new therapeutics that target complex and novel biological targets," said Robert Lum, Ph.D., Telik's Vice President of Technology and Preclinical Development.

TRAP technology exploits the principle that drugs act by adhering to and interacting with cellular proteins. Telik has developed a novel computational approach to determine a molecular fingerprint for each of the over three million compounds in its library. TRAP technology uses these molecular fingerprints to rapidly search the library for promising lead m
'/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Telik Announces Financial Results for 2008 Third Quarter
2. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
3. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
4. Telik Announces Receipt of Nasdaq Notice
5. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
6. ReceptorBio Announces Diabetes License Agreement With Telik
7. Telik Announces Financial Results For 2008 Second Quarter
8. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
9. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
10. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
11. Telik Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s ... and has been known to react more aggressively when hormones ... far from puberty, other acne causing factors like P.acnes bacteria ... threatening skin with unsightly acne scars. Adult acne treatment, Probiotic ... on how to reduce and prevent acne scarring. , ...
(Date:5/17/2013)... Brea, CA (PRWEB) May 17, 2013 IAC ... DisperSol Technologies, a start up laboratory needing to set up ... be moving to a larger facility within a year’s time. ... the knowledge that the laboratory is temporary? What is efficient ... 4 Series modular workstations from IAC Industries. The planners at ...
(Date:5/16/2013)... May 16, 2013 Oven Industries, Inc. ... controllers and temperature sensors since 1964. Expertly ... in industrial control system applications. As one ... includes a generic, control loop feedback system, which helps ... used to adjust a systematic process, using a control ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2New PID Temperature Controllers Announced by Oven Industries Inc. 2
... Oct. 6 Environmental,Tectonics Corporation,s (Amex: ETC ... announced the sale of two (2) BARA-MED(R) XD,Monoplace ... ETC is delighted to work with Saint ... The 597-bed institution,is one of the largest health ...
... 6 Caprion Proteomics Inc. announced,today that it has ... of Allergy and Infectious Diseases (NIAID), a part of ... research in the area,of infectious disease biomarkers., Under ... Caprion,will act as one of two NIAID Clinical Proteomics ...
... AALST , Belgium, AHMEDABAD, India and GOTTINGEN, ... associates,Cardiovascular Center Aalst and J.B. Dahm, MD ... Laboratories joint venture, called imaeon., imaeon ... medical images,analysis for clinical research projects, including ...
Cached Biology Technology:Environmental Tectonics Corporation Announces the Placement of Two Monoplace Hyperbaric Chambers at Saint Barnabas Medical Center in New Jersey 2Environmental Tectonics Corporation Announces the Placement of Two Monoplace Hyperbaric Chambers at Saint Barnabas Medical Center in New Jersey 3Environmental Tectonics Corporation Announces the Placement of Two Monoplace Hyperbaric Chambers at Saint Barnabas Medical Center in New Jersey 4Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract 2Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm 2
(Date:5/16/2013)... and athletes choose to wear the color red when ... Psychological Science , a journal of the Association ... do with their testosterone levels. , The new study, ... of Sunderland and colleagues, demonstrated that males who chose ... higher testosterone levels than other males who chose blue. ...
(Date:5/16/2013)... are about 23 million years old give unprecedented ... order, one of the most species-rich groups among ... paleontologist Professor Bettina Reichenbacher from the Division of ... and Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich ... fish fossils which they assign to the group ...
(Date:5/16/2013)... around the world are meeting next week in ... showcase the latest in research findings about the ... understanding the disorders that affect them., "Canada is ... will showcase the best of neuroscience research done ... President of the Canadian Association for Neuroscience. He ...
Breaking Biology News(10 mins):High-testosterone competitors more likely to choose red 2Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 37th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... Netherlands: Transferring just one embryo at a time to ... diagnosis (PGD) and freezing at the blastocyst stage has ... that were as good as those for blastocysts that ... freezing. Their results mean that it will be possible ...
... discovered gene expression differences that could lead to better ... arthritis (JIA). Eventually such findings could enable doctors to ... more severe arthritis, while those likely to have milder ... a greater risk of side effects. The researchers were ...
... Dallas, TX (June 29, 2009) -- A team of experts ... the South African bilateral amputee track athlete, have just published ... Some of their previously confidential findings were presented to ... in May of 2008. Other findings are now being ...
Cached Biology News:Single thawed embryo transfer after PGD does not affect pregnancy rates 2Single thawed embryo transfer after PGD does not affect pregnancy rates 3Gene expression findings a step toward better classification and treatment of juvenile arthritis 2Gene expression findings a step toward better classification and treatment of juvenile arthritis 3Oscar Pistorius: Previously confidential study results released on amputee sprinter 2
1M stock solution (238mg/ml)...
...
Request Info...
... Clone/PAD: ZMD.330. Immunogen: Synthetic peptide ... of rat and mouse protein kinase C ... the rat and mouse PKCzeta protein. ... does not cross-react with PKCiota/lambda. Reactivity: ...
Biology Products: